Achilles Therapeutics plc
NASDAQ:ACHL
1.045 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 4.731 | 3.688 | 3.288 | 0.778 | 0.303 | 0 |
| Gross Profit
| -4.731 | -3.688 | -3.288 | -0.778 | -0.303 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 67.646 | 57.263 | 42.224 | 22.629 | 9.072 | 4.802 |
| General & Administrative Expenses
| 17.009 | 21.12 | 21.971 | 11.098 | 4.703 | 2.099 |
| Selling & Marketing Expenses
| 12.327 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 17.009 | 21.12 | 21.971 | 11.098 | 4.703 | 2.099 |
| Other Expenses
| -9.4 | 7.318 | 3.133 | 0.531 | -0.215 | 0 |
| Operating Expenses
| 75.255 | 78.383 | 64.195 | 33.727 | 13.775 | 6.887 |
| Operating Income
| -75.255 | -78.383 | -64.195 | -33.727 | -13.775 | -6.901 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 6.081 | 7.318 | 3.133 | 0.531 | -0.215 | 0.014 |
| Income Before Tax
| -69.174 | -71.065 | -61.062 | -33.196 | -13.99 | -6.887 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.491 | 0.111 | 0.037 | 0.003 | 0.13 | 0 |
| Net Income
| -69.665 | -71.176 | -61.099 | -33.199 | -13.99 | -6.887 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.74 | -1.82 | -2.13 | -0.82 | -8.52 | -12.71 |
| EPS Diluted
| -1.74 | -1.82 | -2.13 | -0.82 | -8.52 | -12.69 |
| EBITDA
| -70.442 | -74.693 | -60.907 | -32.955 | -13.473 | -6.728 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |